跳至主要内容
临床试验/CTRI/2026/01/101591
CTRI/2026/01/101591尚未招募3 期

A Randomised Controlled Clinical Trial to evaluate the efficacy and safety of Pramehnil Tablet an Ayurvedic formulation in management of Kaphaj Prameha w.s.r.to type 2 Diabetes Mellitus

Kirti Sachdeva1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2026年2月2日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
90
试验地点
1

研究概览

简要总结

It is a randomised ,prospective ,open label ,interventional  controlled  clinical trial.The trial consist of two groups ,one will receive trial drug Pramehnil  tablet and second group will receive control drug BGR 34. Chane in the subjective and objective parameters of kaphaj prameha or type 2 DM will be the end point of study

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
30.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • Patient freshly diagnosed or already diagnosed between the age of 30 years to 70 years with HbA1c range between 6.5 to 9 also having symptoms pf type 2 DM or kaphaj prameha and willing to give consent for participation.

排除标准

  • Patient not willing to give consent below the age of 30 and above the age of 70 with high HbA1c more than 9 also having complication of type 2 DM like neuropathy retinopathy nephrophathy also patient of type 1 DM Pancreatitis any other serious medical condition like malignancy pregnent and lactating mothers also excluded.

研究者

发起方
Kirti Sachdeva
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr.Kirti Sachdeva

M.S.Regional Ayurveda Research Institute

研究点 (1)

Loading locations...

相似试验